Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Phospho-eIF4E (p-eIF4E) is essential for cancer cell proliferation but not normal cells, making it a potential anti-tumor target.
• Existing therapies targeting p-eIF4E are limited, necessitating the development of novel therapeutic agents.

Purpose of the Study:

• To identify and characterize small molecules that antagonize p-eIF4E function for anti-leukemia therapy.
• To investigate the mechanism of action of homoharringtonine (HHT) in acute myeloid leukemia (AML) cells.

Main Methods:

• In vitro and in vivo studies using AML models.
• Analysis of p-eIF4E levels and function following HHT treatment.
• Investigation of molecular pathways involving SUMOylation and proteasomal degradation.

Main Results:

• Homoharringtonine (HHT) effectively eradicates AML cells expressing high p-eIF4E levels.
• HHT selectively reduces p-eIF4E levels without affecting total eIF4E (t-eIF4E).
• HHT induces p-eIF4E oligomerization and degradation via SUMOylation and the proteasome pathway, targeting the serine 209 residue.

Conclusions:

• The small molecule HHT demonstrates significant anti-leukemia activity by targeting p-eIF4E.
• The phosphorylated serine 209 residue of p-eIF4E is a viable target for novel small molecule-based leukemia therapies.
• HHT represents a promising therapeutic strategy for AML patients with high p-eIF4E expression.